Rx Product News (November 2016)

KYLEENAMARKETED BY: Bayer

INDICATION: The FDA has approved Kyleena, a progestin-containing intrauterine system, for the prevention of pregnancy for up to 5 years.

DOSAGE FORM: 1 sterile intrauterine system consisting of a T-shaped polyethylene frame with a steroid reservoir containing 19.5 mg of levonorgestrel

FOR MORE INFORMATION: bayer.us

YOSPRALAMARKETED BY: Aralez Pharmaceuticals

INDICATION: The FDA has approved Yosprala, a once-daily, fixed-dose combination of aspirin and omeprazole for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin-associated gastric ulcers.

DOSAGE FORM: Tablets: 81 mg of aspirin/40 mg of omeprazole or 325 mg of aspirin/40 mg of omeprazole

FOR MORE INFORMATION: yosprala.com

STELARAMARKETED BY: Janssen

INDICATION: The FDA has approved Stelara (ustekinumab) for the treatment of moderately to severely active Crohn’s disease in adults who have failed or were intolerant to treatment with immunomodulators or corticosteroids, but never failed treatment with a tumor necrosis factor (TNF) blocker or who failed or were intolerant to treatment with 1 or more TNF blockers.

DOSAGE FORM: Intravenous infusion: 260, 390, or 520 mg, followed by 90-mg subcutaneous maintenance injections every 8 weeks

FOR MORE INFORMATION: stelarainfo.com

INVOKAMET XRMARKETED BY: Janssen

INDICATION: The FDA has approved Invokamet XR, a once-daily, fixed-dose combination of canagliflozin and metformin hydrochloride extended-release (XR). Invokamet XR is indicated for first-line use as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes.

DOSAGE FORM: Tablets: 50 or 150 mg of canagliflozin and 500 mg or 1000 mg of metformin XR

FOR MORE INFORMATION: janssen.com